Glenmark gets FDA green light for generic Evoclin
Evoclin Foam had a market value of approximately $12 million for the 12 months endedJuly 2021, according to IQVIA.
Patients with acne will soon have a new generic treatment.
Glenmark has received the Food and Drug Administration’s permission for clindamycin phosphate foam, 1%.
[Read more: Glenmark obtains FDA nod for generic Brovana]
The medication is the generic of Mylan’s Evoclin Foam, 1%.
Evoclin Foam had a market value of approximately $12 million for the 12 months ended July 2021, according to IQVIA.
[Read more: FDA clears Glenmark's generic Firazyr]